Publicaciones en las que colabora con Ramón San Miguel Elcano (12)

2019

  1. Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments

    Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 7, pp. 699-708

2018

  1. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals

    Revista Espanola de Enfermedades Digestivas, Vol. 110, Núm. 10, pp. 621-628

2017

  1. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients

    Expert Review of Gastroenterology and Hepatology, Vol. 11, Núm. 1, pp. 85-93

2016

  1. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 16, Núm. 2, pp. 285-294

  2. Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis

    Medicina Clinica, Vol. 146, Núm. 2, pp. 61-64

  3. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence

    Expert Review of Gastroenterology and Hepatology, Vol. 10, Núm. 11, pp. 1289-1303

2015

  1. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C

    Gut, Vol. 64, Núm. 8, pp. 1277-1288

2014

  1. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: A systematic review of published literature

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, Núm. 3, pp. 387-402

2013

  1. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients

    PharmacoEconomics, Vol. 31, Núm. 10, pp. 919-931

2011

  1. Fe de errores de Role of «health-reated quality of life» measurements in the design of drug clinical trials (Farmacia Hospitalaria (2010) 34, 1, (16-22))

    Farmacia Hospitalaria

2010

  1. Role of "health-related quality of life" measurements in the design of drug clinical trials

    Farmacia Hospitalaria, Vol. 34, Núm. 1, pp. 16-22

2003

  1. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon

    Alimentary Pharmacology and Therapeutics, Vol. 17, Núm. 6, pp. 765-773